GH Research is a Dublin-based biotech, focused on developing a novel and proprietary inhalable 5- Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapy for the treatment of patients with Treatment Resistant Depression (TRD). The company is also researching an injectable formulation of the drug.
The company currently has filed four patents patents for its drug candidates, GH001 and GH002. You can learn more about it’s pipeline here.
Stock Performance
GH Research News 17 articles
- GH Research showcases Phase 2b GH001 posters at ASCP annual meeting
- GH Research to present new GH001 Phase 2b data in treatment-resistant depression at ASCP 2026
- GH Research reports Q1 2026 results and progress toward GH001 Phase 3
- GH Research publishes GH001 Phase 2b depression data in JAMA Psychiatry
- FDA lifts clinical hold on GH001, clearing path for global Phase 3 in 2026
- GH Research reports Q3 2025 results with $293.9 million cash and durable 5-MeO-DMT data
- GH Research Q2 2025: strong cash position and 73% six-month remission in GH001 extension
- GH Research details global pivotal program for GH001 and full Phase 2b TRD dataset
- GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression
- GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates
- GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights
- GH Research Reports Full Year 2022 Financial Results and Provides Business Updates
- GH Research Provides Business Updates and Highlights Key Upcoming Milestones
- GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates
- GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates
- PRO: A Deeper Dive Into GH Research
- GH Research Files to Go Public Only Two Months After Raising $125 Million